These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 24531303)

  • 1. Prognostic value of 18F-FDG PET/CT in patients with soft tissue sarcoma: comparisons between metabolic parameters.
    Hong SP; Lee SE; Choi YL; Seo SW; Sung KS; Koo HH; Choi JY
    Skeletal Radiol; 2014 May; 43(5):641-8. PubMed ID: 24531303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pretreatment tumor SUV
    Ha SC; Oh JS; Roh JL; Moon H; Kim JS; Cho KJ; Choi SH; Nam SY; Kim SY
    Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):33-40. PubMed ID: 27448574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of the quantitative metabolic volumetric measurement on 18F-FDG PET/CT in Stage IV nonsurgical small-cell lung cancer.
    Liao S; Penney BC; Zhang H; Suzuki K; Pu Y
    Acad Radiol; 2012 Jan; 19(1):69-77. PubMed ID: 22142679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of preoperative metabolic tumor volume and total lesion glycolysis measured by 18F-FDG PET/CT in salivary gland carcinomas.
    Ryu IS; Kim JS; Roh JL; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
    J Nucl Med; 2013 Jul; 54(7):1032-8. PubMed ID: 23670902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
    Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
    Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Total lesion glycolysis by 18F-FDG PET/CT is a reliable predictor of prognosis in soft-tissue sarcoma.
    Choi ES; Ha SG; Kim HS; Ha JH; Paeng JC; Han I
    Eur J Nucl Med Mol Imaging; 2013 Dec; 40(12):1836-42. PubMed ID: 23880967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of metabolic tumor volume measured by 18F-fluorodeoxyglucose positron emission tomography in patients with esophageal carcinoma.
    Hyun SH; Choi JY; Shim YM; Kim K; Lee SJ; Cho YS; Lee JY; Lee KH; Kim BT
    Ann Surg Oncol; 2010 Jan; 17(1):115-22. PubMed ID: 19826877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Volume-Based F-18 FDG PET/CT Imaging Markers Provide Supplemental Prognostic Information to Histologic Grading in Patients With High-Grade Bone or Soft Tissue Sarcoma.
    Andersen KF; Fuglo HM; Rasmussen SH; Petersen MM; Loft A
    Medicine (Baltimore); 2015 Dec; 94(51):e2319. PubMed ID: 26705220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined pre-treatment MRI and 18F-FDG PET/CT parameters as prognostic biomarkers in patients with cervical cancer.
    Miccò M; Vargas HA; Burger IA; Kollmeier MA; Goldman DA; Park KJ; Abu-Rustum NR; Hricak H; Sala E
    Eur J Radiol; 2014 Jul; 83(7):1169-1176. PubMed ID: 24767630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lymph node standardized uptake values at pre-treatment
    Jeong Y; Baek S; Park JW; Joo JH; Kim JS; Lee SW
    Br J Radiol; 2017 Mar; 90(1071):20160239. PubMed ID: 28008776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of volume-based (18)F-fluorodeoxyglucose PET/CT parameters in patients with clinically node-negative oral tongue squamous cell carcinoma.
    Lee SJ; Choi JY; Lee HJ; Baek CH; Son YI; Hyun SH; Moon SH; Kim BT
    Korean J Radiol; 2012; 13(6):752-9. PubMed ID: 23118574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of standardized uptake value and metabolic tumour volume on ¹⁸F-FDG PET/CT in oropharyngeal squamous cell carcinoma.
    Kim JW; Oh JS; Roh JL; Kim JS; Choi SH; Nam SY; Kim SY
    Eur J Nucl Med Mol Imaging; 2015 Aug; 42(9):1353-61. PubMed ID: 26067088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of SUVmax and metabolic tumor volume on 18F-FDG PET/CT in early stage non-small cell lung cancer patients without LN metastasis.
    Yoo IeR; Chung SK; Park HL; Choi WH; Kim YK; Lee KY; Wang YP
    Biomed Mater Eng; 2014; 24(6):3091-103. PubMed ID: 25227018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Volume-based parameters on FDG PET may predict the proliferative potential of soft-tissue sarcomas.
    Kitao T; Shiga T; Hirata K; Sekizawa M; Takei T; Yamashiro K; Tamaki N
    Ann Nucl Med; 2019 Jan; 33(1):22-31. PubMed ID: 30196378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Prognostic value of pretreatment (18)F-FDG PET-CT for patients with advanced diffuse large B-cell lymphoma].
    Ding CY; Guo Z; Sun J; Yang WP; Li TR
    Zhonghua Zhong Liu Za Zhi; 2018 Jul; 40(7):528-533. PubMed ID: 30060362
    [No Abstract]   [Full Text] [Related]  

  • 16. Measurement of tumor volume by PET to evaluate prognosis in patients with advanced non-small cell lung cancer treated by non-surgical therapy.
    Yan H; Wang R; Zhao F; Zhu K; Jiang S; Zhao W; Feng R
    Acta Radiol; 2011 Jul; 52(6):646-50. PubMed ID: 21508201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary tumor standardized uptake value (SUVmax) measured on
    Hui Z; Wei F; Ren H; Xu W; Ren X
    J Cancer Res Clin Oncol; 2020 Oct; 146(10):2595-2605. PubMed ID: 32494919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Whole Body Metabolic Tumor Volume and Total Lesion Glycolysis Predict Survival in Patients with Adrenocortical Carcinoma.
    Satoh K; Patel D; Dieckmann W; Nilubol N; Kebebew E
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S714-20. PubMed ID: 26282908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer.
    Liao S; Penney BC; Wroblewski K; Zhang H; Simon CA; Kampalath R; Shih MC; Shimada N; Chen S; Salgia R; Appelbaum DE; Suzuki K; Chen CT; Pu Y
    Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):27-38. PubMed ID: 21946983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of total lesion glycolysis in patients with advanced non-small cell lung cancer receiving chemotherapy.
    Zaizen Y; Azuma K; Kurata S; Sadashima E; Hattori S; Sasada T; Imamura Y; Kaida H; Kawahara A; Kinoshita T; Ishibashi M; Hoshino T
    Eur J Radiol; 2012 Dec; 81(12):4179-84. PubMed ID: 22884163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.